A Head-to Head Comparison of Risankizumab and Ustekinumab as second line therapy in moderate to severely active Crohn's disease. Roshanov PS, Khanna R. Gastroenterology 2024 Sep 7:S0016-5085(24)05445.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roshanov PS, Khanna R. A Head-to Head Comparison of Risankizumab and Ustekinumab as second line therapy in moderate to severely active Crohn's disease. Gastroenterology 2024 Sep 7:S0016-5085(24)05445.
PMID: 39251166